Home » Stocks » Kannalife

Kannalife, Inc. (KLFE)

Stock Price: $0.473 USD -0.027 (-5.31%)
Updated Oct 19, 2020 3:42 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 35.12M
Revenue (ttm) 23,968
Net Income (ttm) -4.18M
Shares Out 74.25M
EPS (ttm) -0.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 19, 2020
Last Price $0.473
Previous Close $0.500
Change ($) -0.027
Change (%) -5.31%
Day's Open 0.500
Day's Range 0.450 - 0.500
Day's Volume 48,346
52-Week Range 0.37 - 5

More Stats

Market Cap 35.12M
Enterprise Value n/a
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 74.25M
Float 15.52M
EPS (basic) n/a
EPS (diluted) -0.06
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta 2.53
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 1,465.30
PB Ratio n/a
Revenue 23,968
Operating Income n/a
Net Income -4.18M
Free Cash Flow n/a
Net Cash n/a
Net Cash / Share n/a
Gross Margin -1,413.03%
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -234.16%
ROE -504.63%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

*No analysts have provided price targets for this stock.

Financial Performance

Financial Overview

No financial data available for this stock yet.

Company Profile

Company Details

Full Name Kannalife, Inc.
Country United States
Employees 5
CEO Dean Petkanas

Stock Information

Ticker Symbol KLFE
Stock Exchange US OTC
Sector Healthcare
Industry Biotechnology
Unique Identifier OTCMKTS: KLFE


Kannalife, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics from its proprietary cannabinoid product platform. It engages in the research and development of chemical entities, such as KLS-13019, as well as its related molecules; and synthetic cannabidiol therapeutics through pre-clinical drug discovery and development processes for use in the disease indications of Overt Hepatic Encephalopathy, Chronic Traumatic Encephalopathy, and Chemotherapy Induced Peripheral Neuropathy. The company was formerly known as TYG Solutions Corp. and changed its name to Kannalife, Inc. in January 2019. Kannalife, Inc. was founded in 2010 and is based in Doylestown, Pennsylvania.